Personalized vaccine joins fight against aggressive breast cancer
NCT ID NCT05325632
Summary
This study is testing whether adding a personalized vaccine to standard chemotherapy and targeted drugs can better treat HER2-positive breast cancer before surgery. The vaccine is made from the patient's own immune cells and aims to train the body to attack the cancer. Researchers will measure if the combination helps eliminate all detectable cancer in the breast and lymph nodes by the time of surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.